The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Determining which CD19-directed CAR-T product is best for each patient with LBCL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on using retrospective statistical analyses of real-world data (RWD) of patients with large B-cell lymphoma (LBCL) to compare CAR-T products and determine which products are most suitable for which patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
